Alzheimer’s disease treatment: The share of herbal medicines

Publish Year: 1400
نوع سند: مقاله ژورنالی
زبان: English
View: 349

This Paper With 13 Page And PDF Format Ready To Download

  • Certificate
  • من نویسنده این مقاله هستم

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

JR_IJBMS-24-2_001

تاریخ نمایه سازی: 19 دی 1399

Abstract:

One of the most frequent forms of dementia in neurological disorders is Alzheimer’s disease (AD). It is a chronic neurodegenerative disease characterized by impaired learning and memory. Pathological symptoms as extracellular amyloid-beta (Aβ) plaques and intracellular accumulation of neurofibrillary tangles occur in AD. Due to the aging of the population and increased prevalence of AD, discovery of new therapeutic agents with the highest effectiveness and fewer side effect seems to be necessary. Numerous synthetic medicines such as tacrine, donepezil, galantamine, rivastigmine, memantine, glutathione, ascorbic acid, ubiquinone, ibuprofen, and ladostigil are routinely used for reduction of the symptoms and prevention of disease progression. Nowadays, herbal medicines have attracted popular attention for numerous beneficial effects with little side effects. Lavandula angustifolia, Ginkgo biloba, Melissa officinalis, Crocus sativus, Ginseng, Salvia miltiorrhiza, and Magnolia officinalis have been widely used for relief of symptoms of some neurological disorders. This paper reviews the therapeutic effects of phytomedicines with prominent effects against various factors implicated in the emergence and progression of AD.

Authors

Masoud Soheili

Physiology Research Center, Institute for Basic Sciences, Kashan University of Medical Sciences, Kashan, Iran

Mohammad Karimian

Department of Molecular and Cell Biology, Faculty of Basic Sciences, University of Mazandaran, Babolsar, Iran

Gholamali Hamidi

Physiology Research Center, Institute for Basic Sciences, Kashan University of Medical Sciences, Kashan, Iran

Mahmoud Salami

Physiology Research Center, Institute for Basic Sciences, Kashan University of Medical Sciences, Kashan, Iran

مراجع و منابع این Paper:

لیست زیر مراجع و منابع استفاده شده در این Paper را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود Paper لینک شده اند :
  • 1. Soheili M, Tavirani MR, Salami M. Lavandula angustifolia extract ...
  • 2. Salami M, Alinaghipour A, Daneshvar R, Hamidi GA, Agahi ...
  • 3. World Health Organization. Neurological disorders: public health challenges. Switzerland: ...
  • 4. Alzheimer’s Disease International. World Alzheimer Report 2016, Improving healthcare ...
  • 5. Kashani MS, Tavirani MR, Talaei SA, Salami M. Aqueous ...
  • 6. Blaisdell AP. Mental imagery in animals: Learning, memory, and ...
  • 7. Ritvo VJH, Turk-Browne NB, Norman KA. Nonmonotonic plasticity: How ...
  • 8.  Rowland HA, Hooper NM, Kellett KAB. Modelling sporadic Alzheimer’s ...
  • 9. Israel MA, Yuan SH, Bardy C, Reyna SM, Mu ...
  • 10. Kondo T, Asai M, Tsukita K, Kutoku Y, Ohsawa ...
  • 11. Mulder SD, Nielsen HM, Blankenstein MA, Eikelenboom P, Veerhuis ...
  • 12. Howes MJ, Houghton PJ. Ethnobotanical treatment strategies against Alzheimer’s ...
  • 13. Cheignon C, Tomas M, Bonnefont-Rousselot D, Faller P, Hureau ...
  • 14. Westergard L, Christensen HM, Harris DA. The cellular prion ...
  • 15. Latta CH, Brothers HM, Wilcock DM. Neuroinflammation in Alzheimer’s ...
  • 16. Akhondzadeh S, Abbasi SH. Herbal medicine in the treatment ...
  • 17. Shi J, Ni J, Lu T, Zhang X, Wei ...
  • 18. Wu JG, Wang YY, Zhang ZL, Yu B. Herbal ...
  • 19. Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten ...
  • 20. Steiner H, Fukumori A, Tagami S, Okochi M. Making ...
  • 21. Bergstrom P, Agholme L, Nazir FH, Satir TM, Toombs ...
  • 22. Sato N, Morishita R. The roles of lipid and ...
  • 23. Arbel-Ornath M, Hudry E, Eikermann-Haerter K, Hou S, Gregory ...
  • 24. Saido T, Leissring MA. Proteolytic degradation of amyloid beta-protein. ...
  • 25. Metaxas A, Kempf SJ. Neurofibrillary tangles in Alzheimer’s disease: ...
  • 26. Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Sarmiento J, Troncoso ...
  • 27. Stancu IC, Vasconcelos B, Terwel D, Dewachter I. Models ...
  • 28. Spillantini MG, Murrell JR, Goedert M, Farlow MR, Klug ...
  • 29. Li F, Tsien JZ. Memory and the NMDA receptors. ...
  • 30. Rapp A, Gmeiner B, Huttinger M. Implication of apoE ...
  • 31. Snyder EM, Nong Y, Almeida CG, Paul S, Moran ...
  • 32. Dzamba D, Harantova L, Butenko O, Anderova M. Glial ...
  • 33. Seixas da Silva GS, Melo HM, Lourenco MV, Lyra ...
  • 34. Buttini M, Masliah E, Yu GQ, Palop JJ, Chang ...
  • 35. Kandemirli F, Saracoglu M, Kovalishyn V. Human acetylcholinesterase inhibitors: ...
  • 36. Day T, Greenfield SA. A non-cholinergic, trophic action of ...
  • 37. Mufson EJ, Ginsberg SD, Ikonomovic MD, DeKosky ST. Human ...
  • 38. Pacheco G, Palacios-Esquivel R, Moss DE. Cholinesterase inhibitors proposed ...
  • 39.    Reale M, Di Nicola M, Velluto L, D’Angelo C, ...
  • 40.    Richter N, Beckers N, Onur OA, Dietlein M, Tittgemeyer ...
  • 41.    Ceylan H, Budak H, Kocpinar EF, Baltaci NG, Erdogan ...
  • 42. Nakabeppu Y. Molecular pathophysiology of insulin depletion, mitochondrial dysfunction, ...
  • 43. Roberts LJ, Fessel JP. The biochemistry of the isoprostane, ...
  • 44. Reed TT. Lipid peroxidation and neurodegenerative disease. Free Radic ...
  • 45. Cosin-Tomas M, Senserrich J, Arumi-Planas M, Alquezar C, Pallas ...
  • 46. Simunkova M, Alwasel SH, Alhazza IM, Jomova K, Kollar ...
  • 47.    Rosini M, Simoni E, Caporaso R, Basagni F, Catanzaro ...
  • 48. de la Monte SM, Wands JR. Molecular indices of ...
  • 49. Eckman J, Dixit S, Nackenoff A, Schrag M, Harrison ...
  • 50. Bueler H, Fischer M, Lang Y, Bluethmann H, Lipp ...
  • 51. van Delft MF, Huang DC. How the Bcl-2 family ...
  • 52. Barry AE, Klyubin I, Mc Donald JM, Mably AJ, ...
  • 53. Whitehouse IJ, Miners JS, Glennon EB, Kehoe PG, Love ...
  • 54. Kawahara M, Kuroda Y, Arispe N, Rojas E. Alzheimer’s ...
  • 55.    O’Banion MK. COX-2 and Alzheimer’s disease: potential roles in ...
  • 56. Hoozemans JJ, van Haastert ES, Veerhuis R, Arendt T, ...
  • 57. Kimura M, Asada T, Uno M, Machida N, Kasuya ...
  • 58. Walker KA, Ficek BN, Westbrook R. Understanding the role ...
  • 59. Kolstoe SE, Ridha BH, Bellotti V, Wang N, Robinson ...
  • 60. Borisovskaya A, Pascualy M, Borson S. Cognitive and neuropsychiatric ...
  • 61. Alzheimer’s disease in France: too many patients exposed to ...
  • 62.  Lipton SA. Paradigm shift in NMDA receptor antagonist drug ...
  • 63. Allison AC, Cacabelos R, Lombardi VR, Alvarez XA, Vigo ...
  • 64. Cai R, Wang LN, Fan JJ, Geng SQ, Liu ...
  • chelating and cholinesterase inhibitors for Alzheimer’s disease. Bioorg Chem 2019; ...
  • 65. Loera-Valencia R, Cedazo-Minguez A, Kenigsberg PA, Page G, Duarte ...
  • 66. Kabir MT, Uddin MS, Begum MM, Thangapandiyan S, Rahman ...
  • 67. Kabir MT, Abu Sufian M, Uddin MS, Begum MM, ...
  • 68. Kim SH, Vlkolinsky R, Cairns N, Fountoulakis M, Lubec ...
  • 69. Mandal PK, Shukla D, Tripathi M, Ersland L. Cognitive ...
  • 70. Deardorff WJ, Grossberg GT. Targeting neuroinflammation in Alzheimer’s disease: ...
  • 71. Weinreb O, Amit T, Bar-Am O, Youdim MB. A ...
  • 72. Weinreb O, Amit T, Bar-Am O, Youdim MB. Ladostigil: ...
  • 73. Soheili M, Khalaji F, Mirhashemi M, Salami M. The ...
  • 74. Zeng Q, Siu W, Li L, Jin Y, Liang ...
  • 75. Soheili M, Rezaei M, Salami M. Anti-acetylcholine esterase activity ...
  • 76. Buyukokuroglu ME, Gepdiremen A, Hacimuftuoglu A, Oktay M. The ...
  • 77. Soheili M, Salami M. Lavandula angustifolia biological characteristics: An ...
  • 78. Hajhashemi V, Ghannadi A, Sharif B. Anti-inflammatory and analgesic ...
  • 79. Hancianu M, Cioanca O, Mihasan M, Hritcu L. Neuroprotective ...
  • 80. Adsersen A, Gauguin B, Gudiksen L, Jager AK. Screening ...
  • 81. Soheili, Salami M, Haghir A, Zali H, Rezaei Tavirani ...
  • 82. Soheili M, Tavirani MR, Salami M. Clearance of amyloid ...
  • 83. Watson K, Hatcher D, Good A. A randomised controlled ...
  • 84. Oskouie AA, Yekta RF, Tavirani MR, Kashani MS, Goshadrou ...
  • 85. Rai VK, Sinha P, Yadav KS, Shukla A, Saxena ...
  • 86. Le Bars PL. Magnitude of effect and special approach ...
  • 87. Napryeyenko O, Borzenko I. Ginkgo biloba special extract in ...
  • 88. Thancharoen O, Limwattananon C. Ginkgo biloba extract (EGb761), cholinesterase ...
  • 89. Waleekhachonloet O, Rattanachotphanit T, Limwattananon P, Limpawattana P, Muller ...
  • 90. Yancheva S, Ihl R, Nikolova G, Panayotov P, Schlaefke ...
  • 91. Kehr J, Yoshitake S, Ijiri S, Koch E, Noldner ...
  • for the cognitive enhancing properties of EGb 761(R). Int Psychogeriatr ...
  • 92. Shi C, Zhao L, Zhu B, Li Q, Yew ...
  • 93. Bastianetto S, Ramassamy C, Dore S, Christen Y, Poirier ...
  • 94. Smith JV, Luo Y. Elevation of oxidative free radicals ...
  • 95. Yao ZX, Han Z, Drieu K, Papadopoulos V. Ginkgo ...
  • 96. Colciaghi F, Borroni B, Zimmermann M, Bellone C, Longhi ...
  • 97. Jahanshahi M, Nikmahzar E, Yadollahi N, Ramazani K. Protective ...
  • 98. Nikmahzar E, Jahanshahi M, Babakordi F. Ginkgo biloba extract ...
  • 99. Shi C, Liu J, Wu F, Yew DT. Ginkgo ...
  • 100.    Du ZY, Li XY. Effects of ginkgolides on interleukin-1, ...
  • 101.    Shi C, Fang L, Yew DT, Yao Z, Xu ...
  • 102.    Shi C, Xiao S, Liu J, Guo K, Wu ...
  • 103.    Smith JV, Luo Y. Studies on molecular mechanisms of ...
  • 104.    Rimbach G, Gohil K, Matsugo S, Moini H, Saliou ...
  • 105.    Sasaki K, Hatta S, Wada K, Ueda N, Yoshimura ...
  • 106.    Maclennan KM, Darlington CL, Smith PF. The CNS effects ...
  • 107.    Miraj S, Rafieian K, Kiani S. Melissa officinalis L. ...
  • 108.    Smith PF, Maclennan K, Darlington CL. The neuroprotective properties ...
  • 109.    Ude C, Paulke A, Nöldner M, Schubert-Zsilavecz M, Wurglics ...
  • 110.    Ehsani A, Alizadeh O, Hashemi M, Afshari A, Aminzare ...
  • 111.    Pereira RP, Fachinetto R, de Souza Prestes A, Puntel ...
  • 112.    Taiwo AE, Leite FB, Lucena GM, Barros M, Silveira ...
  • 113.    Bounihi A, Hajjaj G, Alnamer R, Cherrah Y, Zellou ...
  • 114.    Mencherini T, Picerno P, Scesa C, Aquino R. Triterpene, ...
  • 115.    Lopez V, Martin S, Gomez-Serranillos MP, Carretero ME, Jager ...
  • 116.    Sofowora A, Ogunbodede E, Onayade A. The role and ...
  • 117.    Javid AZ, Haybar H, Dehghan P, Haghighizadeh MH, Mohaghegh ...
  • 118.    Bolkent S, Yanardag R, Karabulut-Bulan O, Yesilyaprak B. Protective ...
  • 119.    Luno V, Gil L, Olaciregui M, Jerez RA, de ...
  • 120.    Huang L, Abuhamdah S, Howes MJ, Dixon CL, Elliot ...
  • 121.    Kennedy DO, Scholey AB, Tildesley NT, Perry EK, Wesnes ...
  • 122.    Soodi M, Naghdi N, Hajimehdipoor H, Choopani S, Sahraei ...
  • 123.    Leśniewicz A, Jaworska K, Żyrnicki W. Macro- and micro-nutrients ...
  • 124.    Abuhamdah S, Huang L, Elliott MS, Howes MJ, Ballard ...
  • 125.    Pereira RP, Boligon AA, Appel AS, Fachinetto R, Ceron ...
  • 126.    Hassanzadeh G, Pasbakhsh P, Akbari M, Shokri S, Ghahremani ...
  • 127.    Qian J, Chen X, Chen X, Sun C, Jiang ...
  • 128.    Kanakis CD, Tarantilis PA, Tajmir-Riahi HA, Polissiou MG. Crocetin, ...
  • 129.    Papandreou MA, Kanakis CD, Polissiou MG, Efthimiopoulos S, Cordopatis ...
  • 130.    Moure A, Franco D, Sineiro J, Dominguez H, Nunez ...
  • 131.    Alavizadeh SH, Hosseinzadeh H. Bioactivity assessment and toxicity of ...
  • 132.    Farahmand SK, Samini F, Samini M, Samarghandian S. Safranal ...
  • 133.    Ochiai T, Ohno S, Soeda S, Tanaka H, Shoyama ...
  • 134.    Bisti S, Maccarone R, Falsini B. Saffron and retina: ...
  • 135.    Ochiai T, Soeda S, Ohno S, Tanaka H, Shoyama ...
  • 136.    Mousavi SH, Tayarani NZ, Parsaee H. Protective effect of ...
  • 137.    Asadi F, Jamshidi AH, Khodagholi F, Yans A, Azimi ...
  • 138.    Finley JW, Gao S. A Perspective on Crocus sativus ...
  • 139.    Sugiura M, Shoyama Y, Saito H, Abe K. The ...
  • 140.    Akhondzadeh S, Fallah-Pour H, Afkham K, Jamshidi AH, Khalighi-Cigaroudi ...
  • 141.    Batarseh YS, Bharate SS, Kumar V, Kumar A, Vishwakarma ...
  • RA. Crocus sativus extract tightens the blood-brain barrier, reduces amyloid ...
  • 142.    Sahoo AK, Dandapat J, Dash UC, Kanhar S. Features ...
  • 143.    Ghahghaei A, Bathaie SZ, Kheirkhah H, Bahraminejad E. The ...
  • 144.    Wang J, Sun C, Zheng Y, Pan H, Zhou ...
  • 145.    Remya C, Dileep KV, Tintu I, Variyar EJ, Sadasivan ...
  • 146.    Kim YJ, Joo SC, Shi J, Hu C, Quan ...
  • 147.    Xiong X, Huang G, Huang H. The anti-oxidant activities ...
  • 148.    Choi JG, Kim N, Huh E, Lee H, Oh ...
  • 149.    Zhao HF, Li Q, Li Y. Long-term ginsenoside administration ...
  • 150.    Dong L, Wang Y, Lv J, Zhang H, Jiang ...
  • 151.    Lyubimov, II, Borzenkov VM, Chepurnova NE, Chepurnov SA. Effect ...
  • 152.    Nishijo H, Uwano T, Zhong YM, Ono T. Proof ...
  • 153.    Ye R, Li N, Han J, Kong X, Cao ...
  • 154.    Cong WH, Liu JX, Xu L. [Effects of extracts ...
  • 155.    Jiang ZL, Chen YR, Zhou C, Shi JS, Duan ...
  • 156.    Kim YC, Kim SR, Markelonis GJ, Oh TH. Ginsenosides ...
  • 157.    Ahn S, Singh P, Castro-Aceituno V, Yesmin Simu S, ...
  • 158.    Kim SJ, Jeong HJ, Yi BJ, Kang TH, An ...
  • 159.    Song SB, Tung NH, Quang TH, Ngan NT, Kim ...
  • 160.    Lee SM. Anti-inflammatory effects of ginsenosides Rg5, Rz1 , ...
  • 161.    Kang S, Kim J-E, Song N, Jung S, Lee ...
  • 162.    He SB, Zhang BX, Wang HH, Wang Y, Qiao ...
  • 163.    Yang L, Miao ZQ, Yang G, Shao AJ, Huang ...
  • 164.    Zhang XZ, Qian SS, Zhang YJ, Wang RQ. Salvia ...
  • 165.    Wong KK, Ho MT, Lin HQ, Lau KF, Rudd ...
  • 166.    Zhang F, Zheng W, Pi R, Mei Z, Bao ...
  • 167.    Jiang WY, Jeon BH, Kim YC, Lee SH, Sohn ...
  • 168.    Huang YS, Zhang JT. [Anti-oxidative effect of three water-soluble ...
  • 169.    Huimin Yu LY, Hongzu Zhou, Sichang Qu, Xianghai Zeng, ...
  • 170.    Mei Z, Zhang F, Tao L, Zheng W, Cao ...
  • 171.    Lee YW, Kim DH, Jeon SJ, Park SJ, Kim ...
  • 172.    Cao YY, Wang L, Ge H, Lu XL, Pei ...
  • 173.    Zhong GX, Li P, Zeng LJ, Guan J, Li ...
  • 174.    Durairajan SS, Yuan Q, Xie L, Chan WS, Kum ...
  • 175.    Hu L, Yu J, Li F, Chen B, Li ...
  • 176.    Liu CS, Chen NH, Zhang JT. Protection of PC12 ...
  • 177.    Zhang N, Kang T, Xia Y, Wen Q, Zhang ...
  • 178.    Liu T, Jin H, Sun QR, Xu JH, Hu ...
  • 179.    Wang Q, Yu X, Patal K, Hu R, Chuang ...
  • 180.    Joe Y, Zheng M, Kim HJ, Kim S, Uddin ...
  • 181.    Ren Y, Houghton PJ, Hider RC, Howes MJ. Novel ...
  • 182.    Kim DH, Jeon SJ, Jung JW, Lee S, Yoon ...
  • 183.    Chen Y, Wu X, Yu S, Fauzee NJ, Wu ...
  • 184.    Qian YH, Xiao Q, Xu J. The protective effects ...
  • 185.    Man Y, Yang L, Zhang D, Bi Y. Cryptotanshinone ...
  • 186.    Song WZ, Cui JF, Zhang GD. [Studies on the ...
  • 187.    Zhang P, Liu X, Zhu Y, Chen S, Zhou ...
  • 188.    Dikalov S, Losik T, Arbiser JL. Honokiol is a ...
  • 189.    Hoi CP, Ho YP, Baum L, Chow AH. Neuroprotective ...
  • 190.    Lee YJ, Choi DY, Yun YP, Han SB, Kim ...
  • 191.    Lee YJ, Lee YM, Lee CK, Jung JK, Han ...
  • 192.    Lee YK, Yuk DY, Kim TI, Kim YH, Kim ...
  • 193.    Oh JH, Kang LL, Ban JO, Kim YH, Kim ...
  • 194.    Kim BH, Cho JY. Anti-inflammatory effect of honokiol is ...
  • 195.    Lin YR, Chen HH, Ko CH, Chan MH. Neuroprotective ...
  • 196.    Lee JW, Lee YK, Lee BJ, Nam SY, Lee ...
  • 197.    Lee YJ, Choi DY, Han SB, Kim YH, Kim ...
  • 198.    Chen YL, Lin KF, Shiao MS, Chen YT, Hong ...
  • 199.    Wu L, Chen C, Cheng C, Dai H, Ai ...
  • 200.    Hou YC, Chao PD, Chen SY. Honokiol and magnolol ...
  • 201.    Matsui N, Takahashi K, Takeichi M, Kuroshita T, Noguchi ...
  • 202.    Ho J, Hong C-. Cardiovascular protection of magnolol: ...
  • Cell-type specificity and dose-related effects. J biomed sci 2012; 19:70. ...
  • نمایش کامل مراجع